
Conference Coverage
3 months ago
How AI Fits Into the Pharmaceutical Supply Chain3 months ago
Why Early RWE Planning Matters for Market AccessLatest Content

Shorts










Podcasts
All News

Bristol Myers Squibb will build a $2.3 billion modular manufacturing campus in Houston, part of a $40 billion five-year US investment pledge.

AMCP's Adam Colborn breaks down survey findings on how health plans and PBMs view the TrumpRx platform.

Dual chokepoint disruptions in the Gulf and Red Sea are pushing shippers toward longer, costlier routes with no resolution in sight.

Gifthealth CEO Chip Parkinson on the factors accelerating direct-to-patient model adoption, and what's next for the channel.

FDA is evaluating small pharmacies' package-level tracing capabilities while extending certain Drug Supply Chain Security Act exemptions to those dispensers through November 2027.

CVS Health is pairing a new Lilly pricing collaboration with a $29 MinuteClinic visit and expanded pharmacist support, disclosed alongside a sharp Q2 earnings beat.

Pharma hub services are evolving as manufacturers navigate specialty therapy growth, digital transformation, vendor transitions, and new models for patient access and support.

In this week's Pharma Pulse, a senior source denies AstraZeneca and Bristol Myers Squibb are in merger talks, Cleveland Clinic and Arrive AI push drone delivery toward pharma's last mile, Kenco's AI rollout signals where 3PL is headed, and TailorMed and WeInfuse team up to expand infusion access.

Cleveland Clinic's new prescription drone delivery program and Arrive AI's planned collaboration with LifeSpan Pharmacy highlight growing interest in drone technology for last-mile logistics.

Kenco has put DeepFabric's AI agents into live production across its 3PL operations, with plans to scale to 20 agents within a year.

Serialization data does more than meet DSCSA rules. See how connected event histories improve recalls, returns and inventory visibility.

Nick Niemeyer of API Innovation Center on how the National Fragility Index could help reduce US drug shortage risk.

Four pharma experts discuss industry trends in M&A, direct-to-patient sales, patient access and commercial strategy at the H1 midyear mark.

The Section 232 tariff deadline for 17 major drugmakers has arrived. Here's what pharma supply chain teams need to know now.

Domestic manufacturing can reduce certain dependencies, but reliable pharmaceutical commercialization requires qualified redundancy, sustainable economics, quality maturity and decision-ready visibility across the full supply network.














